Junshi Bio has partnered with Revitope to develop a new generation of precision-targeted immunotherapy.

Guide: The two sides will work together to develop a "new global" T-cell inset activation cancer therapy with dual antigens as a target!----, Junshi Bio announced today that it has entered into a research and development partnership with Revitope Oncologyusing Revitope's patented protein engineering platform and new antibodies developed by Junshi Bio, the two sides will work together to develop a "new global" T-cell embedded activation cancer therapy with dual antigensRevitope will grant Junshi Bio a global license for products within the framework of this research and development partnershipfor each group of T-cell immunotherapy molecules selected by Junshi, Revitope will receive research and development and commercialization milestones, plus sales sharein addition, Junshi Bio undertakes to invest $10 million in Revitope Oncology in accordance with the terms and conditions of mutual consent, in accordance with all applicable laws, and to convert 9.99 percent of Revitope Oncology's total equityaccording toannouncement, Revitope's dual antigen-oriented T-cell inset activation (TEAC) patented platform can use co-expression of tumor antigens to develop high tumor-specific therapies with better safety and efficacy than traditional immunotherapyRevitope's unique approach is based on a pair of antibodies that target tumors, which share T-cell inlays and are designed as inactive precursors until they encounter cancer cells that co-express double antigens that are activated and thus active against tumors, based on the terms of the development cooperation and license agreement signed by the two parties, Junshi Bio and Revitope will find candidate TEAC pairs based on the targets identified by the partiesRevitope will use its TEAC protein engineering platform to develop up to five new TEAC pairs with optimal pharmacological and therapeutic activity for the patented antibody sequence of Junshiat that time, Junshi Bio will receive TEAC's exclusive global license and will be solely responsible for supporting inditas and all clinical development, manufacturing and commercializationRevitope will pay for clinical development and commercialization milestones paid by Junshi Bio payments for each group of TEAC molecules, plus a share of the product's sales.